We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

KALU:NASDAQKaiser Aluminum Corporation Analysis

Data as of 2026-04-12 - not real-time

$142.67

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Kaiser Aluminum (KALU) is trading at $142.67, well above its 20‑day SMA of $122.30 and the 200‑day SMA of $100.83, yet just shy of the 50‑day SMA of $128.18, indicating a short‑term rally that may be losing steam. The RSI of 69.3 suggests the stock is approaching overbought territory, while a bullish MACD (line $3.82 above signal $0.56) confirms recent momentum but does not guarantee further upside as price nears the resistance level of $144.52. Volatility is elevated at ~50% over the past 30 days and beta of 1.65 points to heightened sensitivity to market swings, compounded by decreasing volume trends. Fundamentally, revenue is growing 21% year‑over‑year with modest gross (13%) and operating (6.4%) margins, a forward EPS of $9.12 and a forward P/E of 15.6, but free cash flow is negative and debt‑to‑equity sits at an extreme 133%, raising concerns about cash generation. The DCF‑derived fair value of $88.67 implies the stock is overvalued by roughly 12‑13%, and the dividend yield of 2.16% is supported by a 45% payout ratio that may be strained given the cash flow profile. Recent news of strong two‑day price momentum and upbeat commentary on aluminum as “the new oil” fuels short‑term enthusiasm, but sector turbulence linked to geopolitical events and the company’s high leverage temper optimism.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • RSI near 70 indicating overbought conditions
  • Price approaching resistance at $144.52
  • Decreasing volume despite recent rally

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Strong revenue growth (21%) and improving forward P/E
  • High leverage (debt‑to‑equity 133%) and negative free cash flow
  • Valuation gap: market price > DCF fair value by ~12%

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Overvaluation relative to intrinsic value and downside potential
  • Elevated sector volatility and beta
  • Sustained cash flow weakness and debt burden

Key Metrics & Analysis

Financial Health

Revenue Growth21.40%
Profit Margin3.34%
P/E Ratio21.0
ROE14.34%
ROA4.66%
Debt/Equity133.25
P/B Ratio2.8
Op. Cash Flow$111.4M
Free Cash Flow$-76712496

Technical Analysis

TrendNeutral
RSI69.3
Support$105.45
Resistance$144.52
MA 20$122.30
MA 50$128.18
MA 200$100.83
MACDBullish
VolumeDecreasing
Fear & Greed Index87.09

Valuation

Fair Value$88.67
Target Price$124.50
Upside/Downside-12.74%
GradeOvervalued
TypeGrowth
Dividend Yield2.16%

Risk Assessment

Beta1.65
Volatility50.24%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.